Cardiome Pharma Corp Company Profile (NASDAQ:CRME)

About Cardiome Pharma Corp (NASDAQ:CRME)

Cardiome Pharma Corp logoCardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CRME
  • CUSIP: N/A
  • Web: www.cardiome.com
Capitalization:
  • Market Cap: $138.24 million
  • Outstanding Shares: 31,927,000
Average Prices:
  • 50 Day Moving Avg: $3.44
  • 200 Day Moving Avg: $3.04
  • 52 Week Range: $2.35 - $5.75
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -39.36
  • P/E Growth: -0.24
Sales & Book Value:
  • Annual Revenue: $23.37 million
  • Price / Sales: 5.92
  • Book Value: $0.88 per share
  • Price / Book: 4.92
Profitability:
  • EBIDTA: ($15,620,000.00)
  • Net Margins: -93.43%
  • Return on Equity: -92.96%
  • Return on Assets: -38.52%
Debt:
  • Debt-to-Equity Ratio: 0.48%
  • Current Ratio: 4.65%
  • Quick Ratio: 4.19%
Misc:
  • Average Volume: 94,852 shs.
  • Beta: 1.07
  • Short Ratio: 1.86
 

Frequently Asked Questions for Cardiome Pharma Corp (NASDAQ:CRME)

What is Cardiome Pharma Corp's stock symbol?

Cardiome Pharma Corp trades on the NASDAQ under the ticker symbol "CRME."

How were Cardiome Pharma Corp's earnings last quarter?

Cardiome Pharma Corp (NASDAQ:CRME) issued its quarterly earnings data on Monday, May, 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.05. The firm had revenue of $5.19 million for the quarter, compared to analysts' expectations of $6.96 million. Cardiome Pharma Corp had a negative return on equity of 92.96% and a negative net margin of 93.43%. The business's revenue for the quarter was down 26.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.06) EPS. View Cardiome Pharma Corp's Earnings History.

Where is Cardiome Pharma Corp's stock going? Where will Cardiome Pharma Corp's stock price be in 2017?

5 equities research analysts have issued twelve-month price targets for Cardiome Pharma Corp's stock. Their forecasts range from $3.50 to $10.00. On average, they anticipate Cardiome Pharma Corp's stock price to reach $6.31 in the next year. View Analyst Ratings for Cardiome Pharma Corp.

Are investors shorting Cardiome Pharma Corp?

Cardiome Pharma Corp saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 103,857 shares, an increase of 32.2% from the April 13th total of 78,546 shares. Based on an average trading volume of 66,191 shares, the short-interest ratio is presently 1.6 days.

Who are some of Cardiome Pharma Corp's key competitors?

Who owns Cardiome Pharma Corp stock?

Cardiome Pharma Corp's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Westfield Capital Management Co. LP (15.34%), Clough Capital Partners L P (9.27%), Stonepine Capital Management LLC (8.64%), AlphaOne Investment Services LLC (1.73%), Sabby Management LLC (0.86%) and Renaissance Technologies LLC (0.79%). View Institutional Ownership Trends for Cardiome Pharma Corp.

Who sold Cardiome Pharma Corp stock? Who is selling Cardiome Pharma Corp stock?

Cardiome Pharma Corp's stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Westfield Capital Management Co. LP, Sabby Management LLC, Clough Capital Partners L P and AlphaOne Investment Services LLC. View Insider Buying and Selling for Cardiome Pharma Corp.

Who bought Cardiome Pharma Corp stock? Who is buying Cardiome Pharma Corp stock?

Cardiome Pharma Corp's stock was bought by a variety of institutional investors in the last quarter, including Knott David M, JPMorgan Chase & Co. and Renaissance Technologies LLC. View Insider Buying and Selling for Cardiome Pharma Corp.

How do I buy Cardiome Pharma Corp stock?

Shares of Cardiome Pharma Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cardiome Pharma Corp stock cost?

One share of Cardiome Pharma Corp stock can currently be purchased for approximately $4.33.

Analyst Ratings

Consensus Ratings for Cardiome Pharma Corp (NASDAQ:CRME) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $6.31 (45.79% upside)

Analysts' Ratings History for Cardiome Pharma Corp (NASDAQ:CRME)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/8/2017HC WainwrightSet Price TargetBuy$10.00LowView Rating Details
12/22/2016Leerink SwannInitiated CoverageOutperform$4.75N/AView Rating Details
11/9/2016Bloom BurtonReiterated RatingBuyN/AView Rating Details
10/12/2016MackieReiterated RatingSpeculative Buy -> Hold$5.10 -> $3.50N/AView Rating Details
8/15/2016Brean CapitalReiterated RatingBuy$10.00 -> $7.00N/AView Rating Details
3/13/2016Canaccord GenuityReiterated RatingBuy$10.00N/AView Rating Details
8/14/2015LB SecuritiesReiterated RatingBuy$12.50N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Cardiome Pharma Corp (NASDAQ:CRME)
Earnings by Quarter for Cardiome Pharma Corp (NASDAQ:CRME)
Earnings History by Quarter for Cardiome Pharma Corp (NASDAQ:CRME)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/20173/31/2017($0.15)($0.20)$6.96 million$5.19 millionViewN/AView Earnings Details
3/7/2017Q4($0.16)($0.18)$6.72 million$7.00 millionViewListenView Earnings Details
11/7/2016Q316($0.20)($0.19)$5.68 million$5.20 millionViewListenView Earnings Details
8/9/2016Q216($0.19)($0.37)$6.73 million$5.90 millionViewN/AView Earnings Details
5/13/2016Q116($0.21)($0.06)$6.34 million$7.10 millionViewListenView Earnings Details
3/10/2016Q415($0.19)($0.37)$7.74 million$4.70 millionViewListenView Earnings Details
11/13/2015Q315($0.23)($0.31)$7.08 million$5.00 millionViewListenView Earnings Details
8/5/2015Q215($0.25)($0.43)$7.67 million$5.70 millionViewN/AView Earnings Details
5/13/2015Q115($0.28)($0.23)$7.48 million$5.50 millionViewListenView Earnings Details
3/12/2015Q414($0.14)($0.39)$8.54 million$7.00 millionViewN/AView Earnings Details
11/7/2014Q314($0.13)($0.26)$6.20 million$7.81 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.16)($0.26)$6.77 million$7.67 millionViewN/AView Earnings Details
5/12/2014Q114($0.11)($0.20)$8.08 million$7.60 millionViewN/AView Earnings Details
3/27/2014($0.22)($0.53)ViewN/AView Earnings Details
11/6/2013Q3 13($0.21)($0.29)ViewN/AView Earnings Details
8/2/2013Q2 13($0.19)($0.22)ViewN/AView Earnings Details
5/13/2013Q113$1.48$1.47$1.60 millionViewN/AView Earnings Details
3/15/2013Q412($0.05)$0.13$0.84 millionViewN/AView Earnings Details
11/13/2012Q312($0.11)($0.22)ViewN/AView Earnings Details
11/4/2011($0.10)($0.12)ViewN/AView Earnings Details
5/16/2011($0.11)($0.12)ViewN/AView Earnings Details
3/10/2011($0.08)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cardiome Pharma Corp (NASDAQ:CRME)
2017 EPS Consensus Estimate: ($0.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.12)($0.09)($0.11)
Q2 20172($0.16)($0.14)($0.15)
Q3 20172($0.13)($0.11)($0.12)
Q4 20172($0.17)($0.14)($0.16)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cardiome Pharma Corp (NASDAQ:CRME)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cardiome Pharma Corp (NASDAQ:CRME)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Cardiome Pharma Corp (NASDAQ:CRME)
Latest Headlines for Cardiome Pharma Corp (NASDAQ:CRME)
Source:
DateHeadline
americanbankingnews.com logoCardiome Pharma Corp (CRME) Sees Significant Increase in Short Interest
www.americanbankingnews.com - May 21 at 10:26 PM
finance.yahoo.com logoCardiome Pharma Corp. :CRME-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017
finance.yahoo.com - May 19 at 4:22 PM
finance.yahoo.com logoCardiome Pharma (CRME) Looks Good: Stock Moves 6.1% Higher
finance.yahoo.com - May 18 at 10:54 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for Cardiome Pharma Corp (CRME) Increased by Analyst
www.americanbankingnews.com - May 18 at 8:20 AM
streetinsider.com logoCardiome Pharma (CRME) Names Justin Renz as CFO; Jennifer Archibald Appointed Chief Business Operations Officer
www.streetinsider.com - May 17 at 11:30 AM
finance.yahoo.com logoCardiome (CRME) Q1 Loss Wider Than Expected, Sales Miss
finance.yahoo.com - May 17 at 11:30 AM
americanbankingnews.com logoCardiome Pharma Corp (CRME) Posts Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - May 16 at 4:28 PM
finance.yahoo.com logoCardiome Reports Changes To Senior Management Team
finance.yahoo.com - May 16 at 12:15 PM
finance.yahoo.com logoInvestor Network: Cardiome Pharma Corp. to Host Earnings Call
finance.yahoo.com - May 15 at 4:23 PM
finance.yahoo.com logoCardiome Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 15 at 4:23 PM
finance.yahoo.com logoCardiome reports 1Q loss
finance.yahoo.com - May 15 at 4:23 PM
americanbankingnews.com logo-$0.15 EPS Expected for Cardiome Pharma Corp (CRME) This Quarter
www.americanbankingnews.com - May 12 at 8:28 PM
americanbankingnews.com logoCardiome Pharma Corp (CRME) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 12 at 2:58 PM
americanbankingnews.com logoCardiome Pharma Corp (CRME) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 9 at 8:04 PM
finance.yahoo.com logoCardiome To Hold First Quarter 2017 Financial Results Conference Call On May 15
finance.yahoo.com - May 8 at 9:43 AM
americanbankingnews.com logo Analysts Expect Cardiome Pharma Corp (CRME) Will Announce Quarterly Sales of $7.47 Million
www.americanbankingnews.com - April 26 at 2:23 PM
americanbankingnews.com logoZacks: Analysts Expect Cardiome Pharma Corp (CRME) to Post -$0.15 Earnings Per Share
www.americanbankingnews.com - April 24 at 12:28 PM
americanbankingnews.com logoCardiome Pharma Corp (CRME) Earns Daily Media Impact Score of 0.05
www.americanbankingnews.com - April 22 at 12:01 PM
americanbankingnews.com logoCardiome Pharma Corp (CRME) Receives Daily News Sentiment Rating of 0.05
www.americanbankingnews.com - April 18 at 3:54 PM
americanbankingnews.com logoCardiome Pharma Corp (CRME) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 17 at 3:27 PM
finance.yahoo.com logoCardiome Pharma (CRME) Jumps: Stock Adds 6.6% in Session - Yahoo Finance
finance.yahoo.com - April 11 at 1:04 PM
finance.yahoo.com logoCARDIOME PHARMA CORP Financials
finance.yahoo.com - April 1 at 4:39 PM
seekingalpha.com logoCardiome cleared to commercialize Brinavess in Canada; shares ahead 2%
seekingalpha.com - March 14 at 11:24 PM
streetinsider.com logoCardiome Pharma (CRME) Receives Notice of Compliance for BRINAVESS from Health Canada
www.streetinsider.com - March 14 at 6:22 PM
us.rd.yahoo.com logoCardiome Receives Notice of Compliance from Health Canada for its BRINAVESS NDS
us.rd.yahoo.com - March 14 at 6:22 PM
seekingalpha.com logoCardiome Pharma's (CRME) CEO Bill Hunter on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 8 at 2:33 AM
us.rd.yahoo.com logoCardiome Reports Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 7 at 4:28 PM
seekingalpha.com logoRecent analyst action - Seeking Alpha
seekingalpha.com - December 23 at 4:42 PM
streetinsider.com logoLeerink Partners Starts Cardiome Pharma (CRME) at Outperform
www.streetinsider.com - December 22 at 4:38 PM
finance.yahoo.com logoCoverage initiated on Cardiome Pharma by Leerink Partners
finance.yahoo.com - December 22 at 4:38 PM
streetinsider.com logoCardiome Pharma (CRME) Initiated Commercial Launch of XYDALB in Germany - StreetInsider.com
www.streetinsider.com - December 20 at 9:29 AM
us.rd.yahoo.com logo11:56 am Cardiome Pharma launches XYDALBA in the UK earlier than expected
us.rd.yahoo.com - December 8 at 9:23 PM
streetinsider.com logoCardiome Pharma (CRME) Announces Early Launch of XYDALBA in the U.K. - StreetInsider.com
www.streetinsider.com - December 8 at 4:23 PM
streetinsider.com logoCardiome Pharma (CRME) Moves Closer to XYDALBA Launch in the UK - StreetInsider.com
www.streetinsider.com - November 30 at 9:45 AM
finance.yahoo.com logo8:01 am Cardiome Pharma moves one step closer to launching XYDALBA in the UK
finance.yahoo.com - November 30 at 9:45 AM

Social

Chart

Cardiome Pharma Corp (CRME) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff